|
| Status |
Public on Aug 24, 2020 |
| Title |
Pre-existing tumoral B cell infiltration and impaired genome maintenance correlate with response to chemoradiotherapy in locally advanced rectal cancer (LARC) |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Using Human Genome 4x44 two-color Agilent microarrays, we established the expression profiling of 39 LARC pretreatment tumor samples to elucidate the molecular features associated with response to treatment after neoadjuvant chemoradiotherapy (nCRT).
|
| |
|
| Overall design |
Two color microarrays where Cy5= tumor sample and Cy3= Stratagene Universal Human RNA Reference. This dataset comprises the transcriptomic profiling of 39 consecutive eligible LARC patients who underwent therapy at the Oncology Unit at Bonorino Udaondo Hospital (Buenos Aires, Argentina) from November 2015 to September 2018. This study was approved by the Udaondo Hospital Ethics Committee and the Instituto Leloir Institutional Review Board. All patients signed the approved Informed Consent. All patients were assigned to standard pelvic long course radiotherapy (LCRT: 50.4 Gy in 28 fractions of three-dimensional conformal radiotherapy, 1.8 Gy per fraction, per day) with concurrent capecitabine (825 mg/m2/bid for 28 days), termed hereafter CRT. Patients with a high risk of systemic relapse (EMVI, high mesorectal node burden and LLND) underwent TNT, which comprises pre-treatment before the CRT with three cycles of CAPOX (130 mg/m² of oxaliplatin on day 1 and capecitabine 1000 mg/m²/bid, days 1-14 every 3 weeks). Two cycles of capecitabine monotherapy (850 mg/m²/bid, days 1-14 every 3 weeks) was then administered until response assessment for all patients. Together, TNT and CRT are referred to as nCRT. Response to nCRT was evaluated on the surgical specimen by the pathological tumor regression (pTRG) score proposed by the seventh edition manual of the American Joint Committee on Cancer (AJCC), except for cases where pTRG was unavailable due to complete clinical response or unresectability. pTRG=0-1 and complete clinical responders were considered good responders, while pTRG=2-3 and unresectable patients were considered poor responders. The most relevant clinical variables are summarized in the metadata file; in case you require further information, do not hesitate to contact the authors.
contributor: GENUIT consortium
|
| |
|
| Contributor(s) |
Sendoya JM |
| Citation(s) |
32784964 |
| |
| Submission date |
May 07, 2020 |
| Last update date |
Aug 24, 2020 |
| Contact name |
Juan Martín Sendoya |
| E-mail(s) |
jmsendoya@gmail.com
|
| Organization name |
Fundación Instituto Leloir
|
| Department |
Laboratory of Molecular and Cellular Therapy
|
| Lab |
Genocan
|
| Street address |
Avenida Patricias Argentinas 435
|
| City |
Buenos Aires |
| State/province |
Buenos Aires |
| ZIP/Postal code |
1405 |
| Country |
Argentina |
| |
|
| Platforms (1) |
| GPL13497 |
Agilent-026652 Whole Human Genome Microarray 4x44K v2 (Probe Name version) |
|
| Samples (39)
|
|
| Relations |
| BioProject |
PRJNA631046 |
Less...
More...